Brief: Point Biopharma Reports First Quarter 2023 Financial Results And Provides Business Highlights

POINT Biopharma Global

15/05/2023 12:51

Point Biopharma Global Inc  PNT.O :
    * POINT BIOPHARMA REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS AND
PROVIDES BUSINESS HIGHLIGHTS
    * U.S. FDA GRANTED FAST TRACK DESIGNATION FOR
(177)LU-PNT2002 FOR
TREATMENT OF MCRPC IN APRIL 2023
    * POINT BIOPHARMA GLOBAL - AS OF MARCH 31, HAD ABOUT $519.2
MILLION IN CASH, CASH EQUIVALENTS, AND INVESTMENTS, ANTICIPATED
TO FUND OPERATIONS INTO 2026
    * QTRLY NET LOSS PER SHARE $0.16
    * Q1 EARNINGS PER SHARE VIEW $-0.31 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNXc57mbs 
Further company coverage:  PNT.O